![This stock is up 53% premarket today and could keep on rising](https://i-invdn-com.investing.com/news/LYNXNPEC0K08U_S.jpg)
Please try another search
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company’s proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Gregory Bailey Brown | 71 | 2007 | Independent Director |
John Shannon Cochran | 58 | 2004 | Independent Vice Chairman of the Board |
Daniel Barber | 48 | 2014 | CEO, President & Director |
Jay Lieberman | - | 2022 | Member of Scientific Advisory Board |
Santo J. Costa | 78 | 2015 | Independent Chairman of the Board |
Timothy E. Morris | 63 | 2022 | Independent Director |
Julie Krop | 58 | 2021 | Independent Director |
David B. Golden | - | 2022 | Member of Scientific Advisory Board |
David M. Fleischer | - | 2022 | Member of Scientific Advisory Board |
John Oppenheimer | - | 2022 | Member of Scientific Advisory Board |
David I. Bernstein | - | 2022 | Member of Scientific Advisory Board |
Marco Taglietti | 64 | 2021 | Independent Director |
Ruchi S. Gupta | - | 2022 | Member of Scientific Advisory Board |
Matthew Greenhawt | - | 2022 | Member of Scientific Advisory Board |
Carlos Camargo | - | 2022 | Member of Scientific Advisory Board |
Abigail L. Jenkins | 48 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review